2023-06-30 16:45:01
Santé Publique France has just launched a surveillance action for Chikungunya, of which an upsurge in cases has been observed in the regions of America. At the same time, a vaccine might be developed. The corresponding trials, conducted in the United States, are in any case promising.
The Valneva laboratory is moving towards the creation of a vaccine once morest Chikungunya. The trials currently being conducted in the United States, on a sample of just over 400 people, look promising. The serum produced might eventually become the first vaccine once morest “bent man diseasewhich had violently hit the West Indies 10 years ago.
Chikungunya is, today, one of the viruses most likely to spread globally, due to climate change and the proliferation of mosquitoes. For the Valneva laboratory and the co-author of a study aimed at testing the product under development, it is “iimportant to have an effective vaccine to prepare for future epidemics”.
For the moment, the results of the studies carried out on the vaccine, dubbed VLA 1553, seem promising.
The immune response, in the participants, is conclusive at 28 days; the vaccine is also well tolerated, both in the young and in the elderly.
In terms of side effects, headaches were the most common symptoms; they have been observed in two thirds of people to whom the product has been injected. This is followed by fatigue, as well as muscle and joint pain, experienced by regarding 20% of individuals. More serious events, muscular or hormonal, were reported in 1.5% of the tested, or two participants out of 4,000 who are now fully recovered, say the authors.
Finally, another limit to the work launched: the product, in the current state of knowledge, may not be suitable for immunocompromised people and pregnant women.
Thus, before declaring victory, other studies are absolutely necessary, in endemic regions of the pathology and on other populations.
1688153103
#Chikungunya #vaccine #developed #Valneva #laboratory
